Cancer monitoring is undergoing a profound shift, moving beyond traditional imaging techniques to a new era of precision enabled by molecular blood assays - often called "liquid biopsies." These tests detect minuscule amounts of circulating tumor DNA (ctDNA) in the bloodstream, offering a non-invasive window into the disease's behavior and possibly transforming how cancer is treated and managed. This breakthrough, detailed in research published September 4, 2025, in Nature Medicine, promises earlier detection of recurrence, personalized treatment strategies, and a more proactive approach to cancer care.
Cancer Genetics Testing: Blood Sample Analysis - News Directory 3
By Dr. Jennifer Chen